AHR and glioblastoma: Blocking AhR delays the progression of IDO/TDO-overexpressing tumors and increases the sensitivity of cancer cells to anti-PD-1 therapy (Campesato et al. 2020).Glioblastoma-derived Kyn activates the AhR in TAMs, promoting several mechanisms that drive tumor progression.